Drug Trial Radar · NCT00464308
A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg
Last checked: Nov 20, 2026Latest source record: Apr 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,392
Actual
Start
Nov 2006
Primary completion
May 2008
Study completion May 2008
Sponsor
- Lead sponsor
- Janssen-Cilag Pty LtdJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 23, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare, the number of patients with heartburn and regurgitation symptom resolution after treatment with either rabeprazole 20 mg, esomeprazole 20 mg or esomeprazole 40 mg.
Conditions
- Gastro-oesophageal Reflux
Interventions
EsomeprazoleDrug
20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
RabeprazoleDrug
20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
EsomeprazoleDrug
40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Patients With Complete Resolution of Heartburn by Week 4Time frame: week 4 of treatment
- The Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4Time frame: 4 weeks
- The Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4Time frame: 4 weeks
- The Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4Time frame: 4 weeks
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Belconnen, Australia
Site not named
Bondi Junction, Australia
Site not named
Brookvale, Australia
Site not named
Browns Plains, Australia
Site not named
Campbelltown, Australia
Site not named
Campsie, Australia
Site not named
Caringbah, Australia
Site not named
Castle Hill, Australia
Site not named
Charlestown, Australia
Site not named
Dapto, Australia
Site not named
Darlinghurst, Australia
Site not named
Dubbo, Australia
Site not named
Elizabeth, Australia
Site not named
Fairfield, Australia
Site not named
Hoppers Crossing, Australia
Site not named
Ingleburn, Australia
Site not named
Leichhardt, Australia
Site not named
Maroubra, Australia
Site not named
Melton, Australia
Site not named
Mount Druitt, Australia
Site not named
Oaklands Park, Australia
Site not named
Royal Park, Australia
Site not named
Sydney, Australia
Site not named
Wentworthville, Australia
Site not named
Wyoming, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.